Dr Mike Trower CSO KaNDy Therapeutics will be giving an invited presentation entitled:  ‘Reducing the heat with neurokinin antagonism; a new non-hormonal approach for treating hot flashes and other multiple symptoms of the menopause’; at the 9th International Congress of Neuroendocrinology, Toronto, Canada taking place from July 15th – 18th, 2018.  The presentation will include recent clinical study data on NT-814, KaNDy’s unique, once daily, dual NK-1,3 antagonist, demonstrating that this non-hormonal therapy produces a rapid and profound reduction in debilitating symptoms of the menopause including vasomotor symptoms and night time awakenings.